NCT03866382 RECRUITING Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
NCT06773936 ENROLLING BY INVITATION Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
NCT04550494 RECRUITING Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
NCT03914300 ACTIVE NOT RECRUITING Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
National Cancer Institute (NCI)
NCT06406465 RECRUITING A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
National Cancer Institute (NCI)
NCT03907475 RECRUITING Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
NCT04068194 ACTIVE NOT RECRUITING Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
National Cancer Institute (NCI)
NCT05198830 RECRUITING Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03896503 ACTIVE NOT RECRUITING Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
National Cancer Institute (NCI)
NCT04665739 RECRUITING Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT03739814 RECRUITING Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02834013 ACTIVE NOT RECRUITING Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
NCT05672524 RECRUITING A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
NCT05554328 RECRUITING Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
NCT07328503 NOT YET RECRUITING CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT03191149 RECRUITING Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
National Cancer Institute (NCI)
NCT07328490 NOT YET RECRUITING Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Cancer Institute (NCI)
NCT04334941 ACTIVE NOT RECRUITING Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker
National Cancer Institute (NCI)
NCT04739800 ACTIVE NOT RECRUITING Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
National Cancer Institute (NCI)
NCT07282912 RECRUITING Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Yale University
NCT04595747 ACTIVE NOT RECRUITING Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
National Cancer Institute (NCI)
NCT06694454 NOT YET RECRUITING Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
National Cancer Institute (NCI)
NCT06900595 RECRUITING Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
National Cancer Institute (NCI)
NCT07379580 RECRUITING A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
BioNTech SE
NCT05564377 RECRUITING Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
NCT06317662 RECRUITING Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
National Cancer Institute (NCI)
NCT07109219 RECRUITING Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
AstraZeneca
NCT05053971 RECRUITING Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
National Cancer Institute (NCI)
NCT07012031 RECRUITING Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
National Cancer Institute (NCI)
NCT05691465 RECRUITING Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
NCT06287775 RECRUITING Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04310020 ACTIVE NOT RECRUITING Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
NCT06161532 RECRUITING Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
National Cancer Institute (NCI)
NCT02642042 ACTIVE NOT RECRUITING Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT05564403 ACTIVE NOT RECRUITING Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
NCT02888743 ACTIVE NOT RECRUITING Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03849651 ACTIVE NOT RECRUITING TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
St. Jude Children's Research Hospital
NCT04751370 ACTIVE NOT RECRUITING Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
National Cancer Institute (NCI)
NCT02345265 ACTIVE NOT RECRUITING Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT07439406 NOT YET RECRUITING Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy
McGill University Health Centre/Research Institute of the McGill University Health Centre
NCT02595892 ACTIVE NOT RECRUITING Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT05289687 RECRUITING Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
NCT07220811 RECRUITING Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy
RAPT Therapeutics, Inc.
NCT07443488 NOT YET RECRUITING Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT07227298 RECRUITING A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Pfizer
NCT04771520 RECRUITING Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
M.D. Anderson Cancer Center
NCT06364423 RECRUITING Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
National Cancer Institute (NCI)
NCT06481735 RECRUITING TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
NCT07419243 RECRUITING Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or Oral Immunotherapy
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
NCT06904482 RECRUITING Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Case Comprehensive Cancer Center
NCT06390319 RECRUITING Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital
NCT04195633 RECRUITING Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT06052813 ACTIVE NOT RECRUITING A Study of BN104 in the Treatment of Acute Leukemia
Institut de Recherches Internationales Servier (I.R.I.S.)
NCT03737994 ACTIVE NOT RECRUITING Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03263572 RECRUITING Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03504644 ACTIVE NOT RECRUITING Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
ECOG-ACRIN Cancer Research Group
NCT06406114 RECRUITING Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing
Massachusetts General Hospital
NCT07053059 RECRUITING Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)
M.D. Anderson Cancer Center
NCT04430738 ACTIVE NOT RECRUITING Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT05356104 RECRUITING GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
Chinese University of Hong Kong
NCT05589896 RECRUITING A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
NCT06918132 RECRUITING Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
Mayo Clinic
NCT05918640 RECRUITING Lurbinectedin in FET-Fused Tumors
Children's Hospital of Philadelphia
NCT06830694 RECRUITING Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment
Se-Hoon Lee
NCT02981628 RECRUITING Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
NCT07227870 NOT YET RECRUITING L19IL2/TNF in Patients With Basal Cell Carcinoma
Philogen S.p.A.
NCT05969860 RECRUITING At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Mayo Clinic
NCT07153796 RECRUITING A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06918431 RECRUITING Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center
NCT05788536 RECRUITING A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations
Regeneron Pharmaceuticals
NCT07227350 NOT YET RECRUITING L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Philogen S.p.A.
NCT02396459 ACTIVE NOT RECRUITING Triac Trial II in MCT8 Deficiency Patients
Rare Thyroid Therapeutics International AB
NCT07193511 RECRUITING BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Avenzo Therapeutics, Inc.
NCT07423585 RECRUITING Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
Asrar Alahmadi
NCT07224100 RECRUITING Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
NCT04554914 RECRUITING A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
NCT07038343 RECRUITING AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Avenzo Therapeutics, Inc.
NCT04521231 RECRUITING A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
NCT07146646 RECRUITING Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT06709495 RECRUITING Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
David S Shulman, MD
NCT05929664 RECRUITING Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery
Thomas Jefferson University
NCT03579316 ACTIVE NOT RECRUITING Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT06006013 RECRUITING Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer
Emory University
NCT07214688 RECRUITING Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Hackensack Meridian Health
NCT06943664 NOT YET RECRUITING Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT07059091 RECRUITING Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
Johns Hopkins University
NCT07414927 NOT YET RECRUITING A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy
Shanghai Best-Link Bioscience, LLC
NCT03441061 ACTIVE NOT RECRUITING Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
M.D. Anderson Cancer Center
NCT04726241 RECRUITING The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
PedAL BCU, LLC
NCT05358249 ACTIVE NOT RECRUITING Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Novartis Pharmaceuticals
NCT07415551 NOT YET RECRUITING A Multi Dose, Phase 2 Study of YH35324 in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Yuhan Corporation
NCT06287229 RECRUITING Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
M.D. Anderson Cancer Center
NCT05442515 RECRUITING CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Cancer Institute (NCI)
NCT07260500 RECRUITING A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT02861417 ACTIVE NOT RECRUITING Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
M.D. Anderson Cancer Center
NCT07148557 ACTIVE NOT RECRUITING A Study of Single Dose of LP-003 in Adolescent Subjects
Longbio Pharma
NCT06835387 RECRUITING Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors
Tiago Biachi de Castria
NCT04065399 RECRUITING A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals
NCT03136146 RECRUITING Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
M.D. Anderson Cancer Center
NCT03147612 ACTIVE NOT RECRUITING Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05579132 RECRUITING A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
MSD R&D (China) Co., Ltd.
NCT06533748 RECRUITING Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
NCT05320406 ACTIVE NOT RECRUITING RElugolix VErsus LeUprolide Cardiac Trial
Emory University
NCT07405086 NOT YET RECRUITING Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
OHSU Knight Cancer Institute
NCT03830918 ACTIVE NOT RECRUITING Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy
Jonsson Comprehensive Cancer Center
NCT06533579 RECRUITING Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
NCT06731270 RECRUITING Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
Emory University
NCT04781088 ACTIVE NOT RECRUITING Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Floor Backes, MD
NCT07172256 NOT YET RECRUITING CUE-101with Pembrolizumab for LA-HPV+HNSCCs
Yale University
NCT04585750 RECRUITING The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
NCT07216404 RECRUITING Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Alan Davis
NCT07400029 RECRUITING A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT05465941 RECRUITING PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Mayo Clinic
NCT03938987 RECRUITING Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL)
University of Alberta
NCT06144606 RECRUITING Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)
H. Lee Moffitt Cancer Center and Research Institute
NCT06580301 RECRUITING Study of YK012 in B-cell Acute Lymphoblastic Leukemia
Excyte Biopharma Ltd
NCT07393555 NOT YET RECRUITING Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT02143414 ACTIVE NOT RECRUITING Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT06943534 RECRUITING Omalizumab Weight-Based Dosing Efficacy Trial
Massachusetts General Hospital
NCT05366218 RECRUITING Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
University Hospital Tuebingen
NCT07229339 NOT YET RECRUITING Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT06778408 RECRUITING Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial
University of Vermont Medical Center
NCT07388836 NOT YET RECRUITING Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
Fujian Cancer Hospital
NCT06001385 ACTIVE NOT RECRUITING HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
Center for International Blood and Marrow Transplant Research
NCT07070219 RECRUITING A Study of CTD402 in T-ALL/LBL Patients
BIOHENG THERAPEUTICS US LLC
NCT07242365 ACTIVE NOT RECRUITING Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy
Jonsson Comprehensive Cancer Center
NCT06395103 RECRUITING Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme LLC
NCT05460533 ACTIVE NOT RECRUITING A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
NCT07242547 RECRUITING Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Fundación GECP
NCT07228741 NOT YET RECRUITING Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
St. Jude Children's Research Hospital
NCT07303283 NOT YET RECRUITING Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Kai Hu
NCT07387926 NOT YET RECRUITING Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals
NCT07313852 NOT YET RECRUITING A Study of Inotuzumab and Blinatumomab in People With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT05748171 RECRUITING A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
Pfizer
NCT04999969 ACTIVE NOT RECRUITING Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
AstraZeneca
NCT06810544 RECRUITING Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
NCT06028828 RECRUITING Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
University of California, Irvine
NCT06738368 RECRUITING Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
University of Washington
NCT05440643 ACTIVE NOT RECRUITING Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ALK-Abelló A/S
NCT05340309 ACTIVE NOT RECRUITING Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer
University of Southern California
NCT02721732 ACTIVE NOT RECRUITING Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
NCT07134088 RECRUITING A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen
NCT07073794 RECRUITING Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
NCT07374003 ACTIVE NOT RECRUITING Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Sun Yat-sen University
NCT04262843 ACTIVE NOT RECRUITING Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
NCT04130854 ACTIVE NOT RECRUITING INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
University of Texas Southwestern Medical Center
NCT04910347 RECRUITING Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Yonsei University
NCT06054113 ACTIVE NOT RECRUITING Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
Amgen
NCT07370337 RECRUITING Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal
Eye & ENT Hospital of Fudan University
NCT03642626 ACTIVE NOT RECRUITING MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT02522611 NOT YET RECRUITING Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain
National Institute of Neurological Disorders and Stroke (NINDS)
NCT05674175 RECRUITING Co-administration of CART22-65s and huCART19 for B-ALL
Stephan Grupp MD PhD
NCT06031688 RECRUITING Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06013423 RECRUITING Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
NCT06769126 RECRUITING Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
SWOG Cancer Research Network
NCT04748419 ACTIVE NOT RECRUITING Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab
University of Nebraska
NCT07254871 ACTIVE NOT RECRUITING Study of DM-101PX in Adults With Birch Pollen Allergy
Desentum Oy
NCT05705492 RECRUITING Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
OHSU Knight Cancer Institute
NCT03333616 ACTIVE NOT RECRUITING Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
NCT07356154 RECRUITING A Study of Revumenib and Mezigdomide in People With Leukemia
Memorial Sloan Kettering Cancer Center
NCT03876769 ACTIVE NOT RECRUITING Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Novartis Pharmaceuticals
NCT04486833 RECRUITING Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Genprex, Inc.
NCT05026905 ACTIVE NOT RECRUITING A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
NCT07209215 NOT YET RECRUITING ctDNA-Informed Management of Early-Stage Rectal Cancer
University of California, Davis
NCT03225664 ACTIVE NOT RECRUITING Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced
M.D. Anderson Cancer Center
NCT06137118 RECRUITING AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
AstraZeneca
NCT07347314 RECRUITING Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
National Cancer Center, Japan
NCT04811560 RECRUITING A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Janssen Research & Development, LLC
NCT07349212 NOT YET RECRUITING UKK-0018 is an Immunotherapeutic for Treatment of Peanut Allergies
Ukko Inc
NCT06290193 RECRUITING Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT06648889 RECRUITING Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
Goethe University
NCT05763199 RECRUITING Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
NCT06308588 RECRUITING Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03891784 ACTIVE NOT RECRUITING Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
NCT04983030 ACTIVE NOT RECRUITING Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Boris Juelg, MD PhD
NCT07328425 RECRUITING Clinical Study in Patients With DSRCT
Italian Sarcoma Group
NCT03960840 ACTIVE NOT RECRUITING Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis Pharmaceuticals
NCT04777071 ACTIVE NOT RECRUITING An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
University of Washington
NCT03808610 ACTIVE NOT RECRUITING Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06849986 RECRUITING IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Fudan University
NCT05152472 RECRUITING A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
Centre Leon Berard
NCT07315165 NOT YET RECRUITING Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation
University of Nebraska
NCT04644016 RECRUITING Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Memorial Sloan Kettering Cancer Center
NCT07322341 NOT YET RECRUITING SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
University of Washington
NCT05418010 RECRUITING Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)
Queen Mary University of London
NCT07323056 RECRUITING Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT07323641 NOT YET RECRUITING Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT05657873 RECRUITING A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
Memorial Sloan Kettering Cancer Center
NCT04607954 ACTIVE NOT RECRUITING Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Mayo Clinic
NCT03674411 ACTIVE NOT RECRUITING Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT07091279 RECRUITING Propranolol for Aggression, Self-Injury, and Severe Disruptive Behavior in Adolescents and Adults With Autism
Jeremy Veenstra-vanderweele
NCT06514794 RECRUITING A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Wugen, Inc.
NCT06561074 RECRUITING A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
M.D. Anderson Cancer Center
NCT05830058 RECRUITING Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
City of Hope Medical Center
NCT07312864 RECRUITING Safety and Tolerability Study of a Novel Bioartificial Liver in Liver Failure and Small-for-Size Syndrome
Beijing Friendship Hospital
NCT07304232 RECRUITING Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
Institute of Hematology & Blood Diseases Hospital, China
NCT03583255 ACTIVE NOT RECRUITING Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
M.D. Anderson Cancer Center
NCT06378866 RECRUITING Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Mayo Clinic
NCT05480449 RECRUITING Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Stephan Grupp MD PhD
NCT07304024 RECRUITING A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
University of Colorado, Denver
NCT03410043 ACTIVE NOT RECRUITING Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study
M.D. Anderson Cancer Center
NCT05456698 ACTIVE NOT RECRUITING Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
NCT07301138 NOT YET RECRUITING BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
Ruijin Hospital
NCT07301424 NOT YET RECRUITING Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
University of Alberta
NCT05615389 RECRUITING Pilot Study of MC in Paediatric Palliative Care
Murdoch Childrens Research Institute
NCT04729322 ACTIVE NOT RECRUITING Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
M.D. Anderson Cancer Center
NCT04592237 ACTIVE NOT RECRUITING Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT04407247 ACTIVE NOT RECRUITING Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
NCT03878446 ACTIVE NOT RECRUITING A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
Novo Nordisk A/S
NCT05761171 ACTIVE NOT RECRUITING A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
NCT03634241 ACTIVE NOT RECRUITING Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
M.D. Anderson Cancer Center
NCT07285044 RECRUITING The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
NCT07293247 NOT YET RECRUITING A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Alliance for Clinical Trials in Oncology
NCT04940299 ACTIVE NOT RECRUITING Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
NCT05453500 RECRUITING Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
University of Washington
NCT03128034 RECRUITING 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT07017829 RECRUITING GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT07192237 NOT YET RECRUITING Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04728230 ACTIVE NOT RECRUITING Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial
M.D. Anderson Cancer Center
NCT02971501 ACTIVE NOT RECRUITING Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases
National Cancer Institute (NCI)
NCT03622788 ACTIVE NOT RECRUITING Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
M.D. Anderson Cancer Center
NCT03934372 RECRUITING Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Biosciences International Sàrl
NCT05472948 RECRUITING Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
Sun Yat-sen University
NCT07288034 NOT YET RECRUITING Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
NCT07288580 NOT YET RECRUITING A Clinical Trial of EHT102 Injection in Pediatric Patients With Biallelic hOTOF Mutations
Shanghai Euhearing Therapeutics Co., Ltd
NCT06102057 RECRUITING PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC
TheraOp
NCT06625190 RECRUITING Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
NCT05651594 RECRUITING Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
Roswell Park Cancer Institute
NCT06253663 ACTIVE NOT RECRUITING Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Kite, A Gilead Company
NCT04696575 RECRUITING Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
Roswell Park Cancer Institute
NCT04701307 ACTIVE NOT RECRUITING Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
NCT04079712 ACTIVE NOT RECRUITING Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT07002398 RECRUITING Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt Disease)
VeonGen Therapeutics GmbH
NCT07276360 NOT YET RECRUITING Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda
Uganda Cancer Institute
NCT06518057 RECRUITING Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
University of Washington
NCT06228066 RECRUITING Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
National Cancer Institute (NCI)
NCT02553460 ACTIVE NOT RECRUITING Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
St. Jude Children's Research Hospital
NCT05256290 ACTIVE NOT RECRUITING Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics, Inc.
NCT04145349 ACTIVE NOT RECRUITING CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor
Eli Lilly and Company
NCT06353906 RECRUITING Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
The Netherlands Cancer Institute
NCT06910761 RECRUITING Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer
City of Hope Medical Center
NCT04625647 ACTIVE NOT RECRUITING Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06116682 RECRUITING Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT05642572 RECRUITING Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT07267338 NOT YET RECRUITING Pembrolizumab + MRGOO3 as Neoadjuvant in NPC
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT06678659 RECRUITING A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Recursion Pharmaceuticals Inc.
NCT07252336 RECRUITING A Multicenter Study of CAR-T Cells in Primary Ph+All
Zhejiang University
NCT05570825 RECRUITING SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
University of Washington
NCT06265285 RECRUITING Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Mayo Clinic
NCT06926595 NOT YET RECRUITING Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
Milton S. Hershey Medical Center
NCT04010357 ACTIVE NOT RECRUITING Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
NCT04787263 ACTIVE NOT RECRUITING CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML
Bambino Gesù Hospital and Research Institute
NCT06333314 RECRUITING Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
UNICANCER
NCT06843434 RECRUITING A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Memorial Sloan Kettering Cancer Center
NCT06064903 RECRUITING CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
Bambino Gesù Hospital and Research Institute
NCT06784336 RECRUITING Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation
University of Michigan Rogel Cancer Center
NCT07016230 RECRUITING Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Gustave Roussy, Cancer Campus, Grand Paris
NCT07070323 RECRUITING A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Beijing GoBroad Hospital
NCT05538091 RECRUITING Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Ronald Buckanovich
NCT06316856 RECRUITING CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Beijing GoBroad Hospital
NCT06316427 RECRUITING Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Beijing GoBroad Hospital
NCT07220408 RECRUITING Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Telios Pharma, Inc.
NCT07243938 NOT YET RECRUITING Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET)
Tao Zhang
NCT07244406 RECRUITING Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
Hebei Senlang Biotechnology Inc., Ltd.
NCT05940961 RECRUITING Inotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
Sheng-Li Xue, MD
NCT05786924 RECRUITING Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Institut de Recherches Internationales Servier
NCT05017025 ACTIVE NOT RECRUITING Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03573700 ACTIVE NOT RECRUITING Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT04310007 ACTIVE NOT RECRUITING Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT06799234 ACTIVE NOT RECRUITING Safety and Immunogenicity of a Candidate Rift Valley Fever Vaccine (RVF003)
University of Oxford
NCT07228325 ENROLLING BY INVITATION Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
Nasus Pharma
NCT04060277 ACTIVE NOT RECRUITING Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT05231122 RECRUITING Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
NCT06730347 RECRUITING A Study of Lorigerlimab in Participants With Advanced Solid Tumors
MacroGenics
NCT07227584 NOT YET RECRUITING ALL Backbone in AYAs
Dana-Farber Cancer Institute
NCT02955290 ACTIVE NOT RECRUITING CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Roswell Park Cancer Institute
NCT04067336 RECRUITING First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
NCT06008730 RECRUITING Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer
Emory University
NCT05669664 ACTIVE NOT RECRUITING Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI)
NCT02877303 RECRUITING Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT02727803 RECRUITING Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
NCT04791839 ACTIVE NOT RECRUITING Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Washington University School of Medicine
NCT04205968 RECRUITING Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
SWOG Cancer Research Network
NCT04148430 ACTIVE NOT RECRUITING A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy
Memorial Sloan Kettering Cancer Center
NCT06258525 NOT YET RECRUITING SAMe in Prevention of Oxaliplatin-associated Liver Injury
Cedars-Sinai Medical Center
NCT05271318 RECRUITING Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
TILT Biotherapeutics Ltd.
NCT03110978 ACTIVE NOT RECRUITING Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT06128070 RECRUITING Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
City of Hope Medical Center
NCT07015996 NOT YET RECRUITING Efficacy of Tezepelumab in Peanut Oral Immunotherapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04879121 RECRUITING Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
M.D. Anderson Cancer Center
NCT05909059 RECRUITING CAR T-cell Therapy in Patients With Renal Dysfunction
Northside Hospital, Inc.
NCT05519579 RECRUITING Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Northside Hospital, Inc.
NCT05031897 RECRUITING Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
NCT04919382 RECRUITING Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Dwight Owen
NCT07221760 NOT YET RECRUITING Personalized Antisense Oligonucleotide for A Single Participant (nL62541) With ATN1 Gene Mutation
n-Lorem Foundation
NCT03284385 ACTIVE NOT RECRUITING Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2
National Cancer Institute (NCI)
NCT06847269 RECRUITING CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia
St. Jude Children's Research Hospital
NCT04276870 RECRUITING Orphan Indications for CD19 Redirected Autologous T Cells
Stephan Grupp MD PhD
NCT05453799 ACTIVE NOT RECRUITING Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Northwestern University
NCT06176989 RECRUITING Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
National Cancer Institute (NCI)
NCT03670966 RECRUITING 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT05621317 ACTIVE NOT RECRUITING A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Aravax Pty Ltd
NCT03779854 RECRUITING Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT07170540 NOT YET RECRUITING UNC Cashew Sublingual Immunotherapy
University of North Carolina, Chapel Hill
NCT06938867 RECRUITING Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant
SNIPR Biome Aps.
NCT04128501 RECRUITING Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting
M.D. Anderson Cancer Center
NCT02444741 ACTIVE NOT RECRUITING Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT02392572 RECRUITING ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
NCT03587311 ACTIVE NOT RECRUITING Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT03600701 ACTIVE NOT RECRUITING Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT07206563 NOT YET RECRUITING Penfluridol for Relapsed/Refractory Small Cell Cancers
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT07039877 RECRUITING Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients
Hospital Universitario Dr. Jose E. Gonzalez
NCT06639074 RECRUITING Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
Mayo Clinic
NCT06570915 NOT YET RECRUITING Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
NCT07200921 NOT YET RECRUITING A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills
Beijing Tiantan Hospital
NCT07199855 ACTIVE NOT RECRUITING Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia
Zhejiang University
NCT07200141 NOT YET RECRUITING Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
Peking Union Medical College Hospital
NCT02625480 ACTIVE NOT RECRUITING Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT05500391 RECRUITING Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Centre Oscar Lambret
NCT02498613 ACTIVE NOT RECRUITING A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
NCT04975555 ACTIVE NOT RECRUITING Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
NCT04034927 ACTIVE NOT RECRUITING Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
National Cancer Institute (NCI)
NCT03965689 ACTIVE NOT RECRUITING Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
National Cancer Institute (NCI)
NCT05192889 ACTIVE NOT RECRUITING Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
St. Jude Children's Research Hospital
NCT06069063 NOT YET RECRUITING Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
Allergy & Asthma Medical Group & Research Center
NCT07182708 NOT YET RECRUITING High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC
Peking University Cancer Hospital & Institute
NCT03831932 ACTIVE NOT RECRUITING Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04387227 ACTIVE NOT RECRUITING Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT06704152 RECRUITING BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio, Inc
NCT05751044 RECRUITING HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05745714 RECRUITING HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT07175415 NOT YET RECRUITING HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT05658640 RECRUITING HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT07155122 NOT YET RECRUITING Efficacy and Safety of Serplulimab Combined With Etoposide and Cisplatin as Neoadjuvant Therapy in Limited-Stage Small-Cell Carcinoma of the Esophageal
Fujian Cancer Hospital
NCT03970096 RECRUITING Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Fred Hutchinson Cancer Center
NCT06330584 RECRUITING Administration of Intranasal Midazolam for Anxiety in Palliative Care
Insel Gruppe AG, University Hospital Bern
NCT06865339 RECRUITING Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Nitin Ohri
NCT04546399 RECRUITING A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
NCT04150497 RECRUITING Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
NCT06682793 RECRUITING A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT04404660 ACTIVE NOT RECRUITING A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Autolus Limited
NCT04606914 RECRUITING Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
University of Alabama at Birmingham
NCT05884333 RECRUITING Cord Blood Transplant in Adults With Blood Cancers
Memorial Sloan Kettering Cancer Center
NCT05268003 ACTIVE NOT RECRUITING A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04516070 ACTIVE NOT RECRUITING Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
M.D. Anderson Cancer Center
NCT07155499 ACTIVE NOT RECRUITING A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis.
AO GENERIUM
NCT07152067 NOT YET RECRUITING Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer
Centre Hospitalier Universitaire de Liege
NCT07000162 RECRUITING LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial
Azienda USL Reggio Emilia - IRCCS
NCT06985485 RECRUITING Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy
The First Affiliated Hospital of Soochow University
NCT05576480 RECRUITING SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer
Ruijin Hospital
NCT06492070 RECRUITING Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
NCT03399773 ACTIVE NOT RECRUITING Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
NCT03835767 RECRUITING Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05242965 ACTIVE NOT RECRUITING A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
University of Washington
NCT05695261 RECRUITING Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Rima Rachid
NCT02506933 ACTIVE NOT RECRUITING Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT04111172 ACTIVE NOT RECRUITING A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma
Thomas Jefferson University
NCT07117669 NOT YET RECRUITING Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
N-Fold, LLC
NCT07131033 ACTIVE NOT RECRUITING Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy
The Second People's Hospital of Huai'an
NCT04315324 RECRUITING Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
SWOG Cancer Research Network
NCT03765177 RECRUITING CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
Ottawa Hospital Research Institute
NCT06548490 RECRUITING GLP-1R Agonist Treatment for Opioid Use Disorder
Milton S. Hershey Medical Center
NCT02790515 ACTIVE NOT RECRUITING Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
St. Jude Children's Research Hospital
NCT05667506 RECRUITING A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
Juventas Cell Therapy Ltd.
NCT04684147 RECRUITING Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
NCT07109401 RECRUITING Perioperative Immunotherapy for Resectable Limited-Stage SCLC
Fudan University
NCT05114421 ACTIVE NOT RECRUITING Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
M.D. Anderson Cancer Center
NCT03628612 ENROLLING BY INVITATION Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
Autolus Limited
NCT06213636 RECRUITING Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Essen Biotech
NCT04688736 RECRUITING Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.
Institute of Hematology & Blood Diseases Hospital, China
NCT07022002 RECRUITING SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
Shenyang Sunshine Pharmaceutical Co., LTD.
NCT07094659 RECRUITING Aging and Task-specific Training to Reduce Falls
University of Illinois at Chicago
NCT07090525 RECRUITING Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions
Qingdao Central Hospital
NCT04904588 ACTIVE NOT RECRUITING HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT04469764 RECRUITING Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
Jonsson Comprehensive Cancer Center
NCT05756569 RECRUITING Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
NCT05182385 ACTIVE NOT RECRUITING Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
Goethe University
NCT07085234 RECRUITING Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
The First Affiliated Hospital of Xiamen University
NCT05735717 RECRUITING MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT07084311 ACTIVE NOT RECRUITING Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation
n-Lorem Foundation
NCT06277154 RECRUITING MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
HRYZ Biotech Co.
NCT07079696 NOT YET RECRUITING Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04753970 RECRUITING Retina is a Marker for Cerebrovascular Heath
Mayo Clinic
NCT05883540 RECRUITING Lysergic Acid Diethylamide (LSD) in Palliative Care
University Hospital, Basel, Switzerland
NCT04471974 ACTIVE NOT RECRUITING ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal
NCT03113487 ACTIVE NOT RECRUITING P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
City of Hope Medical Center
NCT05406674 ACTIVE NOT RECRUITING Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer
The Netherlands Cancer Institute
NCT04022213 ACTIVE NOT RECRUITING A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
Memorial Sloan Kettering Cancer Center
NCT07072494 RECRUITING CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
Zhujiang Hospital
NCT05501756 RECRUITING Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Children's Hospital Medical Center, Cincinnati
NCT06220097 ACTIVE NOT RECRUITING Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05173246 RECRUITING JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma
Sun Yat-sen University
NCT06990737 RECRUITING Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
University of California, Davis
NCT03286530 ACTIVE NOT RECRUITING Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
Massachusetts General Hospital
NCT04268550 ACTIVE NOT RECRUITING Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
NCT06453460 RECRUITING CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT
University of California, Irvine
NCT05138757 ACTIVE NOT RECRUITING Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
University of Chicago
NCT03739502 RECRUITING A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
University of Rochester
NCT05805605 RECRUITING Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT05312671 RECRUITING Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06815003 RECRUITING Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT04285671 ACTIVE NOT RECRUITING Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer
Jonsson Comprehensive Cancer Center
NCT07008885 RECRUITING BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Chinese PLA General Hospital
NCT03314974 RECRUITING Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT05920798 RECRUITING Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Mayo Clinic
NCT04055649 RECRUITING ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
Ira Winer
NCT03817320 ACTIVE NOT RECRUITING PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
NCT02650986 ACTIVE NOT RECRUITING Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
Roswell Park Cancer Institute
NCT06703216 NOT YET RECRUITING Pre-emptive Anakinra for Cytokine Event Reduction
Ann & Robert H Lurie Children's Hospital of Chicago
NCT07021677 RECRUITING Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"
Tata Memorial Centre
NCT05800210 RECRUITING Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
University of Florida
NCT04533451 ACTIVE NOT RECRUITING Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT07018063 NOT YET RECRUITING Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer
zhoujing
NCT06959641 RECRUITING XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Northwestern University
NCT07012447 RECRUITING Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
yuejun Liu
NCT06184009 RECRUITING Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Jae Wook Lee
NCT05764928 NOT YET RECRUITING Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy
Rgene Corporation
NCT06257394 RECRUITING Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
Hyoung Jin Kang
NCT05712356 ACTIVE NOT RECRUITING A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics, Inc.
NCT03682289 RECRUITING Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
Rahul Aggarwal
NCT05470777 RECRUITING CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
The First Affiliated Hospital of Soochow University
NCT03984968 RECRUITING CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
NCT06793410 RECRUITING Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation
Vastra Gotaland Region
NCT03104491 RECRUITING Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Leland Metheny
NCT06721884 RECRUITING Herbal Evaluation Of Artemisia Annua For Small Intestinal Bacterial Overgrowth
National University of Natural Medicine
NCT06584552 RECRUITING LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
The University of New South Wales
NCT06986811 RECRUITING CEB-01 in Paediatrics With Locally Resectable Abdominal Tumours
CEBIOTEX
NCT06936566 RECRUITING MAGIC Ruxolitinib for aGVHD
John Levine
NCT03512405 ACTIVE NOT RECRUITING Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
City of Hope Medical Center
NCT05364762 ACTIVE NOT RECRUITING Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
NCT02375620 ACTIVE NOT RECRUITING Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
Changchun GeneScience Pharmaceutical Co., Ltd.
NCT06706427 ACTIVE NOT RECRUITING Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy Subjects
NGGT (Suzhou) Biotechnology Co., Ltd.
NCT06718244 RECRUITING Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
Ruijin Hospital
NCT04941287 ACTIVE NOT RECRUITING Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
NCT03114865 ACTIVE NOT RECRUITING A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT06034561 RECRUITING Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia
Instituto do Cancer do Estado de São Paulo
NCT04482894 ACTIVE NOT RECRUITING Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS
University of Virginia
NCT04957485 ACTIVE NOT RECRUITING Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
SIGA Technologies
NCT04919629 RECRUITING APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Roswell Park Cancer Institute
NCT06686108 RECRUITING Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NCT02983578 ACTIVE NOT RECRUITING Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
M.D. Anderson Cancer Center
NCT06957977 NOT YET RECRUITING A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer
Zhongguang Luo, MD
NCT03509961 RECRUITING The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Pediatric Transplantation & Cellular Therapy Consortium
NCT04544592 RECRUITING UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
NCT02646839 ENROLLING BY INVITATION KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
Michael Pulsipher
NCT06014827 RECRUITING Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
City of Hope Medical Center
NCT05090384 ACTIVE NOT RECRUITING Pediatric GVHD Low Risk Steroid Taper Trial
John Levine
NCT04329325 ACTIVE NOT RECRUITING Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT04163562 RECRUITING Oral Immunotherapy for Peanut Allergic Patients
InnoUp Farma S.L.
NCT06061094 RECRUITING Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
Goethe University
NCT04920968 RECRUITING Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL"
Maria Sklodowska-Curie National Research Institute of Oncology
NCT06924619 RECRUITING Neoadjuvant Radiotherapy for Locally Advanced Unresectable Thymoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
NCT04232241 ACTIVE NOT RECRUITING Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
Universitätsklinikum Hamburg-Eppendorf
NCT03093922 ACTIVE NOT RECRUITING A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Memorial Sloan Kettering Cancer Center
NCT03786692 RECRUITING Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC
Fox Chase Cancer Center
NCT06920173 RECRUITING Pulse Study: Peripheral Use of Low-dose Vasopressors for Safety and Efficacy in the Intensive Care Unit
Kingston Health Sciences Centre
NCT04274426 ACTIVE NOT RECRUITING Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer
AGO Research GmbH
NCT06660407 RECRUITING Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer
Mayo Clinic
NCT04233346 ACTIVE NOT RECRUITING The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Otsuka Beijing Research Institute
NCT06911710 RECRUITING The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
Tianjin Medical University General Hospital
NCT05303792 ACTIVE NOT RECRUITING Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Alliance for Clinical Trials in Oncology
NCT06406777 RECRUITING Chronic Lung Allograft Dysfunction MRI Study
Sean Fain
NCT06839456 RECRUITING Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT04499053 RECRUITING Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Georgetown University
NCT06886074 RECRUITING Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL
Hospital Universitario Dr. Jose E. Gonzalez
NCT04032418 ACTIVE NOT RECRUITING Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer
Roswell Park Cancer Institute
NCT06059391 RECRUITING CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
NCT04747912 RECRUITING Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
University of Chicago
NCT05579639 RECRUITING Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
Children's Hospital Medical Center, Cincinnati
NCT04230356 RECRUITING Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells for Viral Infections After Stem Cell Transplant
Children's Hospital Medical Center, Cincinnati
NCT06836505 RECRUITING Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.
Sun Yat-sen University
NCT06299462 RECRUITING PTCy and ATG for MSD and MUD Transplants
Instituto Nacional de Cancer, Brazil
NCT04781634 RECRUITING a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B-ALL
Chongqing Precision Biotech Co., Ltd
NCT06044311 RECRUITING Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma
Sakti Chakrabarti
NCT06816134 RECRUITING Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia
The First Affiliated Hospital of Soochow University
NCT06564545 RECRUITING A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
The First Affiliated Hospital of Zhengzhou University
NCT06564493 RECRUITING A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
The First Affiliated Hospital of Zhengzhou University
NCT06557161 RECRUITING A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
The First Affiliated Hospital of Zhengzhou University
NCT06559345 RECRUITING A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
The First Affiliated Hospital of Zhengzhou University
NCT06829797 NOT YET RECRUITING A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemotherapy Versus Chemotherapy Alone in the Treatment of Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital
NCT05672108 RECRUITING Phase II Trial of Lung Chemoemobolization
City of Hope Medical Center
NCT06816394 NOT YET RECRUITING Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)
National Taiwan University Hospital
NCT05331170 RECRUITING Viral Mucosal Reprogramming
The University of Texas Medical Branch, Galveston
NCT06777264 NOT YET RECRUITING Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for Newly Diagnosed B-cell ALL Patients in CR1
First Affiliated Hospital of Zhejiang University
NCT06775275 RECRUITING A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
The First Affiliated Hospital of Guangzhou Medical University
NCT05281809 RECRUITING Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister
NCT06179524 RECRUITING CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Beijing Yongtai Ruike Biotechnology Company Ltd
NCT06456359 RECRUITING Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
University Hospital Heidelberg
NCT06766578 NOT YET RECRUITING Clinical Study of Low-dose Interval Radiotherapy Combined With Tirelizumab and SOX Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Shandong Provincial Hospital
NCT06754267 RECRUITING Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
First Affiliated Hospital of Zhejiang University
NCT05967728 ENROLLING BY INVITATION Testing of a System for Remote Ischemic Conditioning in Cerebral Small Vessel Disease and Pre-hospital Stroke Care
University of Calgary
NCT06752382 NOT YET RECRUITING Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
Zhejiang Cancer Hospital
NCT05376111 RECRUITING Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
The First Affiliated Hospital of Soochow University
NCT06742515 RECRUITING Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
First Affiliated Hospital of Zhejiang University
NCT05173896 ACTIVE NOT RECRUITING Improving Cerebral Blood Flow and Cognition in Patients with Cerebral Small Vessel Disease. the ETLAS-2 Trial
Christina Kruuse
NCT06018766 RECRUITING LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Steven Hays, MD
NCT06482086 RECRUITING Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
NCT06713057 NOT YET RECRUITING Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
West China Hospital
NCT04045301 ACTIVE NOT RECRUITING Omalizumab to Accelerate a Symptom-driven Multi-food OIT
Philippe Bégin
NCT06706388 ACTIVE NOT RECRUITING Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene Mutation
n-Lorem Foundation
NCT06393985 RECRUITING Decitabine, Venetoclax and Blinatumomab for Maintenance Following HSCT in Patients With Ph-Negative B-ALL
The First Affiliated Hospital of Soochow University
NCT03971045 RECRUITING Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer
European Institute of Oncology
NCT06686472 RECRUITING Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
Telios Pharma, Inc.
NCT06420076 RECRUITING Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
Essen Biotech
NCT06608732 RECRUITING Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Institute of Hematology & Blood Diseases Hospital, China
NCT06658925 NOT YET RECRUITING Olverembatinib as Maintenance Therapy or Preemptive Therapy After Allo-HSCT in Ph+ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT06097533 RECRUITING Improvement of Quality of Life by Cannabinoids in Oncologic Patients
University Hospital Schleswig-Holstein
NCT03919240 ACTIVE NOT RECRUITING CAR-T Cell Therapy Targeting to CD19 for R/R ALL
The First Affiliated Hospital of Soochow University
NCT04475731 ACTIVE NOT RECRUITING Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT05156060 RECRUITING Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
Natalie Lockney
NCT05501665 RECRUITING Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
Vanderbilt-Ingram Cancer Center
NCT04183712 RECRUITING Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA
Shanghai Jiao Tong University School of Medicine
NCT06635330 RECRUITING Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL
Kara Yakhteh Tajhiz Azma Company
NCT06631040 NOT YET RECRUITING Cell Therapy with Anti-CD19 CAR-NK Cells in Patients with Relapsed or Resistant B-ALL
Shahid Beheshti University of Medical Sciences
NCT04117945 ACTIVE NOT RECRUITING Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
NCT06608342 RECRUITING Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
NCT06065670 NOT YET RECRUITING Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy
University of California, San Francisco
NCT05766800 RECRUITING Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
NCT03541083 ACTIVE NOT RECRUITING Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
Stichting Hemato-Oncologie voor Volwassenen Nederland
NCT06578546 RECRUITING Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL
The First Affiliated Hospital of Soochow University
NCT05832684 ACTIVE NOT RECRUITING Safety and Efficacy of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
Chigenovo Co., Ltd
NCT02949219 ACTIVE NOT RECRUITING Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
Academic and Community Cancer Research United
NCT06416007 RECRUITING Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors
University of Cincinnati
NCT06508099 RECRUITING Vitamin A and D Supplementation in Allogeneic HCT
St. Petersburg State Pavlov Medical University
NCT05334823 RECRUITING A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Chongqing Precision Biotech Co., Ltd
NCT03676504 RECRUITING Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
University Hospital Heidelberg
NCT06518850 NOT YET RECRUITING Study of Clinical Features and Efficacy of Small Intestinal Bacterial Overgrowth in Patients With Abdominal Distension
Peking Union Medical College Hospital
NCT06490341 NOT YET RECRUITING GP Combined With Nimotuzumab and Sintilimab as Induction Therapy for Nasopharyngeal Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT04216316 ACTIVE NOT RECRUITING Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT06477549 RECRUITING BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
St. Petersburg State Pavlov Medical University
NCT06478264 NOT YET RECRUITING A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell Carcinoma
Zhangzhou Municipal Hospital
NCT06467994 RECRUITING Boiled Tree Nut for Oral Immunotherapy in Food-allergic Children
Chinese University of Hong Kong
NCT06465602 RECRUITING Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls
University of Chile
NCT06110572 RECRUITING Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Vanderbilt-Ingram Cancer Center
NCT06464068 RECRUITING AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA
Gruppo Oncologico Italiano di Ricerca Clinica
NCT05269381 RECRUITING Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Mayo Clinic
NCT04891016 RECRUITING Toripalimab Plus FLOT in Locally Advanced Gastric Cancer
Henan Cancer Hospital
NCT06438796 NOT YET RECRUITING Blinatumomab Maintenance After Allo-HSCT
Ruijin Hospital
NCT05310591 RECRUITING Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Assistance Publique - Hôpitaux de Paris
NCT02997761 RECRUITING Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Brian Jonas
NCT03192397 ACTIVE NOT RECRUITING Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT06420973 RECRUITING RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Peking University Cancer Hospital & Institute
NCT03821610 ACTIVE NOT RECRUITING A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
University of Birmingham
NCT05982275 NOT YET RECRUITING Trial of an Investigational Drug After Rejecting the Relapse of an Allogeneic Transplant
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
NCT06147271 ENROLLING BY INVITATION Impact of SGLT2 Inhibitors in Heart Transplant Recipients
Universidade Federal do Ceara
NCT06398405 RECRUITING A Phase II Clinical Study of Epigallocatechin-3-gallate in Patients With Esophageal Squamous Cancer
Shandong Cancer Hospital and Institute
NCT06151743 RECRUITING Neoadjuvant PD-1 Inhibitor Combined With Cetuximab and Platinum in Resectable Locally Advanced Hypopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
NCT06384235 NOT YET RECRUITING Phase II Clinical Study of LTC004 in Patients With mCRC
Letolab
NCT06367114 NOT YET RECRUITING Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NCT03732950 ACTIVE NOT RECRUITING Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
Jonsson Comprehensive Cancer Center
NCT05905315 RECRUITING Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC
The Netherlands Cancer Institute
NCT06206174 RECRUITING TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx, Inc.
NCT06250959 RECRUITING RDC-Blinatumomab Versus hyperCVAD for Ph-negative B-ALL.
Chen Suning
NCT04660760 RECRUITING Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Academic and Community Cancer Research United
NCT04167813 ACTIVE NOT RECRUITING Trial of Ondansetron as a Parkinson's HAllucinations Treatment
University College, London
NCT03024489 ACTIVE NOT RECRUITING Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma
Mahidol University
NCT05693025 RECRUITING Evaluation of the Walk With Ease Program for Fall Prevention
Iowa State University
NCT04601584 RECRUITING GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
AO GENERIUM
NCT06278545 RECRUITING Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Centre Hospitalier Universitaire Dijon
NCT06241807 RECRUITING Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
Shandong Cancer Hospital and Institute
NCT03590171 RECRUITING International Study for Treatment of High Risk Childhood Relapsed ALL 2010
Charite University, Berlin, Germany
NCT06247501 RECRUITING Treatment of CD19 Chimeric Antigen Receptor T Cells for Pediatric Patients With CD19-positive B-cell Acute Lymphoblastic Leukemia Who Are Indicated for Hematopoietic Stem Cell Transplantation
Seoul National University Hospital
NCT06220487 RECRUITING A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Nanfang Hospital, Southern Medical University
NCT05126849 RECRUITING Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After Immunosuppression
Assistance Publique - Hôpitaux de Paris
NCT06141265 RECRUITING Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Peking University Cancer Hospital & Institute
NCT06136988 NOT YET RECRUITING A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NCT05082519 RECRUITING Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Etan Orgel
NCT04222491 ENROLLING BY INVITATION Food Oral Immunotherapy for Peanut Allergy
Massachusetts General Hospital
NCT06081478 RECRUITING CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
Beijing Tongren Hospital
NCT06082934 RECRUITING Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia
Xijing Hospital
NCT05909527 ACTIVE NOT RECRUITING A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma
Guangzhou Bio-gene Technology Co., Ltd
NCT05837052 RECRUITING A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Zhejiang University
NCT05931757 NOT YET RECRUITING A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
The First Affiliated Hospital of Soochow University
NCT05858983 RECRUITING Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy
Frontera Therapeutics
NCT05054296 RECRUITING Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
M.D. Anderson Cancer Center
NCT05754801 NOT YET RECRUITING Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer
Chinese University of Hong Kong
NCT05648019 RECRUITING CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol
KK Women's and Children's Hospital
NCT05757336 RECRUITING Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer
Lu Wang, MD, PhD
NCT04499573 ACTIVE NOT RECRUITING Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
NCT03428802 RECRUITING Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
Rutgers, The State University of New Jersey
NCT03286634 RECRUITING ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
National Hospital Organization Nagoya Medical Center
NCT05397769 RECRUITING Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial.
Sun Yat-sen University
NCT05126186 NOT YET RECRUITING Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Rescuing Patients With Graft Failure
Assistance Publique - Hôpitaux de Paris
NCT05054465 NOT YET RECRUITING A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL
Israeli Medical Association
NCT04746209 RECRUITING Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Medical College of Wisconsin
NCT04989985 RECRUITING S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma
Sixth Affiliated Hospital, Sun Yat-sen University
NCT04834544 RECRUITING A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care
Peking University Third Hospital
NCT03709719 ACTIVE NOT RECRUITING Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia
Assistance Publique - Hôpitaux de Paris
NCT03609398 RECRUITING Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine
U.S. Army Medical Research and Development Command
NCT05554380 SUSPENDED Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
NCT06478953 COMPLETED Impact of Rapid Pathogen Detection in ICU Patients With Suspected Pneumonia on Antimicrobial Therapy
Chinese University of Hong Kong
NCT06297629 WITHDRAWN A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT03066206 TERMINATED Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
M.D. Anderson Cancer Center
NCT04387071 TERMINATED CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
University of Southern California
NCT03913559 TERMINATED Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
NCT06922448 COMPLETED Study of BLU-808 in Allergic Rhinoconjunctivitis
Blueprint Medicines Corporation
NCT05232851 COMPLETED A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer
Mayo Clinic
NCT06705530 COMPLETED A Study to Evaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative Disorders
National Research Center for Hematology, Russia
NCT05551117 TERMINATED A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
MacroGenics
NCT04754425 TERMINATED Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT04505553 COMPLETED Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
NCT05466994 COMPLETED A Phase II Randomized Controlled Trial to Determine the Efficacy of an auGmented reAlity gaMe in pediatrIc caNcer Patients Who Are Opioid Naïve Undergoing Surgery to Reduce Postoperative Opioid Use (GAMING-ON Study)
M.D. Anderson Cancer Center
NCT04148352 TERMINATED Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
Andrew J Long, PharmD
NCT03095352 COMPLETED Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Laura Huppert, MD, BA
NCT03698552 TERMINATED ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04191187 COMPLETED Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
NCT02364713 TERMINATED MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
NCT05440916 COMPLETED Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
University Medical Centre Maribor
NCT05186415 COMPLETED Contrast Enhanced 3D Echocardiographic Quantification of Right Ventricular Volumes in Repaired CHD
Nemours Children's Clinic
NCT03132532 COMPLETED Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
NCT03855332 COMPLETED Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial
University of Oxford
NCT04396535 TERMINATED Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer
Mayo Clinic
NCT03160079 COMPLETED Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
University of California, San Diego
NCT03581487 COMPLETED Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03694002 COMPLETED Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
NCT04035434 TERMINATED A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
CRISPR Therapeutics AG
NCT03910660 COMPLETED A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
NCT03856216 TERMINATED Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT03776812 COMPLETED Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Corcept Therapeutics
NCT03709043 COMPLETED Addressing Heavy Alcohol Use Consumption With Kudzu
Glenn-Milo Santos
NCT03480438 COMPLETED Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab
Goethe University
NCT04985604 TERMINATED Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
NCT04501614 TERMINATED A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Takeda
NCT03044587 COMPLETED Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
AIO-Studien-gGmbH
NCT02962102 COMPLETED Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury
David Leaf
NCT06527937 COMPLETED Pharmacokinetics Study of DESF in Adults With Oral Allergy Syndrome
Aquestive Therapeutics
NCT02458014 COMPLETED Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease
M.D. Anderson Cancer Center
NCT03026062 COMPLETED Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT03776643 COMPLETED Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy
Assistance Publique - Hôpitaux de Paris
NCT04622345 COMPLETED Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
Vanda Pharmaceuticals
NCT03860844 TERMINATED Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Sanofi
NCT03564678 TERMINATED Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT02973997 COMPLETED Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)
Academic and Community Cancer Research United
NCT02498600 COMPLETED Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT02834936 COMPLETED A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation
Jiangsu HengRui Medicine Co., Ltd.
NCT04761822 COMPLETED COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
National Institute of Allergy and Infectious Diseases (NIAID)
NCT05032183 TERMINATED Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT04336943 TERMINATED Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
University of Washington
NCT06009107 WITHDRAWN A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Juventas Cell Therapy Ltd.
NCT05630859 COMPLETED Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.
GlaxoSmithKline
NCT02793544 COMPLETED HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
NCT03033225 COMPLETED Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
Mayo Clinic
NCT04579679 TERMINATED Open-Label Surufatinib in European Patients With NET
Hutchmed
NCT05995275 COMPLETED A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age
ModernaTX, Inc.
NCT04502966 COMPLETED Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04120454 COMPLETED Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer
Ohio State University Comprehensive Cancer Center
NCT02722668 COMPLETED UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
NCT03333486 TERMINATED Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
NCT03382561 COMPLETED Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04530487 TERMINATED Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
NCT04019288 TERMINATED AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
NCT02420717 TERMINATED Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT06140407 TERMINATED Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
NCT03792633 COMPLETED Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL
University of Pennsylvania
NCT02220985 COMPLETED Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
NCT04047355 COMPLETED Propranolol for Challenging Behaviors in Autism
Rutgers, The State University of New Jersey
NCT04902040 TERMINATED Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
NCT03246906 TERMINATED Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
NCT05594784 COMPLETED Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
NCT06393751 WITHDRAWN Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT03108131 COMPLETED Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
M.D. Anderson Cancer Center
NCT05840770 WITHDRAWN Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
NCT02713386 COMPLETED Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
NCT04752163 TERMINATED DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05672095 WITHDRAWN Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
NCT05297760 COMPLETED Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
University of Zurich
NCT03845296 COMPLETED Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
NCT03799328 COMPLETED Low Dose Multi-OIT for Food Allergy (LoMo)
The Hospital for Sick Children
NCT03679676 COMPLETED Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Stanford University
NCT05432388 COMPLETED Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts
Novartis Pharmaceuticals
NCT04340167 COMPLETED Study of Anti-CD22 CAR-T Cells Treating Leukemia Children
Beijing Boren Hospital
NCT04325841 COMPLETED Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children
Beijing Boren Hospital
NCT01125449 WITHDRAWN Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease
Situs Cancer Research Center
NCT05447663 TERMINATED A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
Novartis Pharmaceuticals
NCT04926181 TERMINATED Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Rahul Aggarwal
NCT04556084 TERMINATED Blinatumomab Bridging Therapy for BALL
Michael Burke
NCT04082572 COMPLETED Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers
M.D. Anderson Cancer Center
NCT02756130 WITHDRAWN Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
Jonsson Comprehensive Cancer Center
NCT04993677 COMPLETED A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
NCT03554473 COMPLETED M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
National Cancer Institute (NCI)
NCT03576547 TERMINATED Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT02569957 TERMINATED Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT05239169 COMPLETED Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05275673 TERMINATED A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer
Faeth Therapeutics
NCT03434730 COMPLETED Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
NCT03861702 COMPLETED Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:
Nelson Yee
NCT04925986 TERMINATED Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC
Sarah Goldberg
NCT02487095 COMPLETED Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Cancer Institute (NCI)
NCT06689436 COMPLETED Pivotal BE Study of TAH3311 ODF vs ELIQUIS® Tablet Under Fasted Condition in Healthy Volunteers
TAHO Pharmaceuticals Ltd.
NCT04037891 TERMINATED Topical rVA576 for Treatment of Atopic Keratoconjunctivitis
AKARI Therapeutics
NCT03660878 COMPLETED A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis
Aldeyra Therapeutics, Inc.
NCT04209595 COMPLETED PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers
National Cancer Institute (NCI)
NCT02489903 COMPLETED RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
NCT03206047 COMPLETED Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT05216653 COMPLETED Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM)
Sir Run Run Shaw Hospital
NCT06865352 COMPLETED Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation
Fondazione IRCCS Policlinico San Matteo di Pavia
NCT03158129 COMPLETED Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT02396134 COMPLETED Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02535338 COMPLETED Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02484430 COMPLETED Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02828358 COMPLETED Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
National Cancer Institute (NCI)
NCT03709121 COMPLETED A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber
Aldeyra Therapeutics, Inc.
NCT04095221 COMPLETED A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
NCT03907397 COMPLETED Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
Scott Sicherer
NCT03373071 COMPLETED Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
Bambino Gesù Hospital and Research Institute
NCT03462030 COMPLETED Baked Milk Oral Immunotherapy for Cow's Milk Allergy
Johns Hopkins University
NCT03736720 TERMINATED Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
NCT04538378 TERMINATED Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
National Cancer Institute (NCI)
NCT06108596 COMPLETED Evaluation of the Efficacy and Safety of Interleucin-2 Combined With PD-1 Monoclonal Antibody and CAPOX in Preoperative Neoadjuvant Therapy for Mid-low Locally Advanced Rectal Cancer - a Single-center, Single-arm, Open-label Clinical Trail
The First Affiliated Hospital with Nanjing Medical University
NCT03149315 COMPLETED Inhibition of Anaphylaxis by Ibrutinib
Ann & Robert H Lurie Children's Hospital of Chicago
NCT04551521 COMPLETED CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
NCT03031470 TERMINATED Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Liver Transplantation
Dompé Farmaceutici S.p.A
NCT04856176 TERMINATED A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy
Tufts Medical Center
NCT04083170 TERMINATED Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Fred Hutchinson Cancer Center
NCT04871529 TERMINATED Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
SWOG Cancer Research Network
NCT04046549 COMPLETED A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Amgen
NCT04364048 TERMINATED Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Rachel Sanborn
NCT04029688 TERMINATED A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
NCT02631603 TERMINATED Stop Exogenous Allergic Alveolitis (EAA) in Childhood
Matthias Griese
NCT04789668 COMPLETED Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
M.D. Anderson Cancer Center
NCT03575325 COMPLETED Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
NCT04340154 TERMINATED Study of Sequential CAR-T Cell Treating Leukemia Children
Beijing Boren Hospital
NCT02312245 COMPLETED Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
NCT04872218 COMPLETED Adjuvant Treatment With Abatacept to Promote Remission During Peanut Oral Immunotherapy
Philippe Bégin
NCT03981822 COMPLETED A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
Verrica Pharmaceuticals Inc.
NCT03148275 COMPLETED Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT05113394 WITHDRAWN Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy
Boston Children's Hospital
NCT03101267 COMPLETED A Dose-finding Study of ASP4070
Astellas Pharma Inc
NCT02614066 COMPLETED A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
Kite, A Gilead Company
NCT02953457 COMPLETED Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Roswell Park Cancer Institute
NCT03680131 COMPLETED Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis
Edesa Biotech Inc.
NCT03732352 COMPLETED 18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
NCT06680856 COMPLETED Allogeneic Platelet Rich Plasma (PRP) to Treat Diabetic Foot Ulcers
Ospedale Policlinico San Martino
NCT04762875 TERMINATED MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Ensoma
NCT04987281 WITHDRAWN Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study
M.D. Anderson Cancer Center
NCT04788472 COMPLETED Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Zhejiang University
NCT04151706 COMPLETED CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Robert Lowsky
NCT05191797 TERMINATED Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
University of Washington
NCT06297083 WITHDRAWN Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy
Murdoch Childrens Research Institute
NCT04167657 COMPLETED SinTilimab After Radiation (STAR Study)
Peking Union Medical College Hospital
NCT05557110 COMPLETED Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
Chen Suning
NCT04173507 COMPLETED Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
SWOG Cancer Research Network
NCT03971474 COMPLETED Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
SWOG Cancer Research Network
NCT03679598 COMPLETED Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency
University of Alabama at Birmingham
NCT02773238 COMPLETED FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
University of Washington
NCT04554459 TERMINATED Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
Institute of Hematology and Blood Transfusion, Czech Republic
NCT04931420 WITHDRAWN Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
University of Chicago
NCT04622228 COMPLETED Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer
Hoffmann-La Roche
NCT03488225 TERMINATED Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05936229 WITHDRAWN Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
NCT05009953 TERMINATED Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
CSPC Ouyi Pharmaceutical Co., Ltd.
NCT03088709 TERMINATED Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Loyola University
NCT05364645 WITHDRAWN Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer
SWOG Cancer Research Network
NCT06293820 COMPLETED A Study Of TL-925 For The Treatment of AC
Telios Pharma, Inc.
NCT04969601 COMPLETED Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
Assistance Publique - Hôpitaux de Paris
NCT02581059 TERMINATED Efficacy of Ginseng for Patients on Regorafenib
Wake Forest University Health Sciences
NCT05740449 WITHDRAWN HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Princess Maxima Center for Pediatric Oncology
NCT02199184 COMPLETED Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT05572476 WITHDRAWN Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Institut Bergonié
NCT03292237 COMPLETED Intensive Nutrition in Critically Ill Adults
Australian and New Zealand Intensive Care Research Centre
NCT06210750 WITHDRAWN Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
NCT03678493 COMPLETED A Study of FMT in Patients With AML Allo HSCT in Recipients
Masonic Cancer Center, University of Minnesota
NCT04856865 COMPLETED ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Alladapt Immunotherapeutics, Inc.
NCT04390243 TERMINATED Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
Academic and Community Cancer Research United
NCT05895201 WITHDRAWN High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
NCT05433532 COMPLETED Study of Azacitidine,Venetoclax,and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients
The First Affiliated Hospital of Soochow University
NCT03623854 COMPLETED Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma
Jonsson Comprehensive Cancer Center
NCT02340884 COMPLETED A Pilot RCT of the PRISM Intervention for AYAs With Cancer
Seattle Children's Hospital
NCT03201458 COMPLETED Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
NCT04410653 COMPLETED Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
NCT04554485 COMPLETED Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL)
Institute of Hematology and Blood Transfusion, Czech Republic
NCT02992964 TERMINATED Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers
The Hospital for Sick Children
NCT05243719 TERMINATED Open-label Extension Study of ADP101
Alladapt Immunotherapeutics, Inc.
NCT03504774 TERMINATED Food Allergen OIT for Shrimp and Cashew
Sayantani B. Sindher
NCT06103656 COMPLETED E-B-FAHF-2, Multi OIT and Xolair for Food Allergy
New York Medical College
NCT03056339 COMPLETED Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT04204980 COMPLETED Desensitization in Kidney Allograft Using Daratumumab
Assistance Publique - Hôpitaux de Paris
NCT05613348 WITHDRAWN CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
Zhujiang Hospital
NCT03267030 COMPLETED Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase
Birgitte Klug Albertsen
NCT03925532 COMPLETED Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT04071171 COMPLETED Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation
Medical University Innsbruck
NCT02923739 TERMINATED Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
NCT03982992 WITHDRAWN Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab
Ludwig-Maximilians - University of Munich
NCT05726682 WITHDRAWN A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Sanofi
NCT04845035 WITHDRAWN Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
University of Michigan Rogel Cancer Center
NCT03063619 COMPLETED Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
M.D. Anderson Cancer Center
NCT02901899 COMPLETED Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Northwestern University
NCT02435849 COMPLETED Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Novartis Pharmaceuticals
NCT03682770 COMPLETED Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Regeneron Pharmaceuticals
NCT06124404 COMPLETED Step 1 of A Two-step Trial to Evaluate the Effectiveness and Safety of Remimazolam Besylate for Sedation in ICU Patients
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NCT05838885 COMPLETED A Trial of YPEG-rhGH in Children With Short Stature
Xiamen Amoytop Biotech Co., Ltd.
NCT04494789 COMPLETED Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS
The George Institute
NCT03083691 COMPLETED BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer
Lung Cancer Group Cologne
NCT03422679 TERMINATED Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Cellestia Biotech AG
NCT04785547 TERMINATED ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT
Prof. Christina Peters
NCT05045443 COMPLETED Safety and Efficacy of Curcumin in Children With Acute Lymphoblastic Leukemia
Ain Shams University
NCT04956666 COMPLETED A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Institut de Recherches Internationales Servier
NCT03245658 WITHDRAWN The Effect of Cannabis in Pancreatic Cancer
Jens Rikardt Andersen
NCT05201183 WITHDRAWN A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Naoyuki G. Saito, M.D., Ph.D.
NCT02709343 COMPLETED Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction
The University of Queensland
NCT02578914 COMPLETED A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis
Aldeyra Therapeutics, Inc.
NCT03559413 COMPLETED Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL
University Children's Hospital Tuebingen
NCT03431168 COMPLETED A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV
University of Alabama at Birmingham
NCT02639559 COMPLETED Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies
Washington University School of Medicine
NCT02763384 TERMINATED BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Washington University School of Medicine
NCT03995667 TERMINATED Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
OHSU Knight Cancer Institute
NCT05901532 COMPLETED Nasal Irrigation With Chinese Herbal Medicine as an Adjunctive Treatment in Allergic Rhinitis
Taichung Veterans General Hospital
NCT03649841 TERMINATED Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
University of Washington
NCT04269811 COMPLETED Flu-Bu-Mel Conditioning Regimen for Myeloid Disease
Shanghai Jiao Tong University School of Medicine
NCT04308785 TERMINATED A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer
Hoffmann-La Roche
NCT05161533 WITHDRAWN Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
NCT02500797 COMPLETED Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02899728 TERMINATED Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT03366103 TERMINATED Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
NCT03468985 COMPLETED Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT04977479 COMPLETED The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02608411 TERMINATED TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)
Istituto Oncologico Veneto IRCCS
NCT03096782 COMPLETED Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT05038904 COMPLETED Preventing Anaphylaxis With Acalabrutinib
Johns Hopkins University
NCT05295589 WITHDRAWN Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
NCT03733249 TERMINATED Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
NCT04989283 WITHDRAWN Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02661035 COMPLETED Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT02831933 TERMINATED Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma
Eric Bernicker, MD
NCT05045404 WITHDRAWN Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT04088760 TERMINATED TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders
Children's Hospital Medical Center, Cincinnati
NCT05320380 WITHDRAWN A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat
Children's Oncology Group
NCT04224571 COMPLETED CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children
Chinese University of Hong Kong
NCT04974970 TERMINATED Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy
University Hospital, Geneva
NCT05935774 WITHDRAWN OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
University of Washington
NCT04029038 WITHDRAWN Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
M.D. Anderson Cancer Center
NCT03882203 COMPLETED CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
Shanghai Jiao Tong University School of Medicine
NCT03832192 COMPLETED Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study
Victor Wang
NCT04072445 COMPLETED Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer
Mayo Clinic
NCT04639245 TERMINATED Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Fred Hutchinson Cancer Center
NCT05973292 COMPLETED Endocrowns in Anterior Teeth: Effect of Cementation Protocols and Restorative Materials on the Clinical Performance of the Restorations
Kafrelsheikh University
NCT03267186 COMPLETED Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant
Andrew Rezvani
NCT04971187 TERMINATED Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT02920021 COMPLETED Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy
AnaptysBio, Inc.
NCT05432674 COMPLETED Digital Fall Prevention Study
Brigham and Women's Hospital
NCT02311998 COMPLETED Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
M.D. Anderson Cancer Center
NCT04954326 COMPLETED A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)
Institut de Recherches Internationales Servier
NCT03779191 COMPLETED Alectinib in Combination With Bevacizumab in ALK Positive NSCLC
Instituto Nacional de Cancerologia de Mexico
NCT03359863 COMPLETED Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
University of California, San Francisco
NCT04562792 COMPLETED Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
Children's Mercy Hospital Kansas City
NCT02520141 COMPLETED Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT03473574 COMPLETED Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
AIO-Studien-gGmbH
NCT04372927 TERMINATED ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
NCT03705507 TERMINATED International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
University of Birmingham
NCT03389035 COMPLETED Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT
Fondazione Matilde Tettamanti Menotti De Marchi Onlus
NCT02581007 COMPLETED Reduced Intensity Conditioning Transplant Using Haploidentical Donors
Northside Hospital, Inc.
NCT03548467 COMPLETED A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer
Nykode Therapeutics ASA
NCT04067518 COMPLETED A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier
NCT05180201 COMPLETED SEPSIS: L. Plantarum Trial
The Hospital for Sick Children
NCT02978183 COMPLETED Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis
Noveome Biotherapeutics, formerly Stemnion
NCT03406468 COMPLETED Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer
Maastricht Radiation Oncology
NCT03726021 COMPLETED Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer
Qingdao Central Hospital
NCT03109093 COMPLETED Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia
Goethe University
NCT04323657 COMPLETED TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
NCT03231969 COMPLETED A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model
Faes Farma, S.A.
NCT04156659 WITHDRAWN Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL
Novartis Pharmaceuticals
NCT04117477 TERMINATED Xylitol - Healthcare Associated Infection Reduction in Stem Cell Transplant Patients
Children's Hospital Medical Center, Cincinnati
NCT02743351 COMPLETED Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
NCT04225676 TERMINATED Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Novartis Pharmaceuticals
NCT03251508 COMPLETED Salvage Peanut Oral Immunotherapy Study
University of North Carolina, Chapel Hill
NCT02658812 TERMINATED Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT02593123 COMPLETED Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis
Virginia Commonwealth University
NCT02807883 COMPLETED Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04753216 COMPLETED Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Northwestern University
NCT05411861 COMPLETED Post-Operative Pain and Opioid Reduction Trial After Bunionectomy
Cali Pharmaceuticals LLC
NCT04926194 COMPLETED Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
University Health Network, Toronto
NCT03012165 COMPLETED A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Aldeyra Therapeutics, Inc.
NCT03617913 COMPLETED Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
NCT04800627 TERMINATED Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
M.D. Anderson Cancer Center
NCT03883906 COMPLETED Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant
Children's Hospital Medical Center, Cincinnati
NCT02412306 COMPLETED Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Amgen
NCT05571540 WITHDRAWN Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
Kunming Hope of Health Hospital
NCT04200989 WITHDRAWN Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy
Scripps Health
NCT03518112 TERMINATED Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT04928820 TERMINATED 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy
Jonsson Comprehensive Cancer Center
NCT03320434 COMPLETED Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
ORA, Inc.
NCT04282174 WITHDRAWN CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
Baptist Health South Florida
NCT04335578 TERMINATED A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
UCB Biopharma SRL
NCT04265534 TERMINATED KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Calithera Biosciences, Inc
NCT02967133 TERMINATED A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Alliance Foundation Trials, LLC.
NCT03455140 COMPLETED A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
University of Birmingham
NCT05254912 COMPLETED Photoallergic Potential of 6% Bemotrizinol
DSM Nutritional Products, Inc.
NCT04532710 COMPLETED Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Marinomed Biotech AG
NCT03473340 TERMINATED Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
University of Michigan
NCT04560686 TERMINATED Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
NCT03523429 TERMINATED PETHEMA-BLIN-01/PET069014 (BLIN-01)
PETHEMA Foundation
NCT03029598 COMPLETED Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
NCT03023046 COMPLETED Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
NCT03050060 TERMINATED Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
NCT03275818 COMPLETED Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma
Grupo Espanol de Investigacion en Sarcomas
NCT05022394 WITHDRAWN Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study
M.D. Anderson Cancer Center
NCT03793608 COMPLETED Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
Regeneron Pharmaceuticals
NCT03410446 COMPLETED Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care
University Health Network, Toronto
NCT02749968 COMPLETED Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma
University of Cincinnati
NCT04754815 WITHDRAWN Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC
Shirish Gadgeel
NCT03966742 COMPLETED Doxorubicin Eluting Intra-arterial Embolization for Aggressive Desmoid Fibromatosis
Rabin Medical Center
NCT03668392 TERMINATED Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)
Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT02750215 COMPLETED A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Massachusetts General Hospital
NCT04056299 TERMINATED Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Aimmune Therapeutics, Inc.
NCT04061590 WITHDRAWN Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer
University of California, San Francisco
NCT04448834 WITHDRAWN Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL
Dorothy Sipkins, MD, PhD
NCT04044560 TERMINATED Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
University of British Columbia
NCT03868423 WITHDRAWN Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
Sameek Roychowdhury
NCT04673591 COMPLETED Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
T-Balance Therapeutics GmbH
NCT02392637 COMPLETED Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
M.D. Anderson Cancer Center
NCT03851081 WITHDRAWN Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
NCT02304991 COMPLETED FARE Peanut SLIT and Early Tolerance Induction
University of North Carolina, Chapel Hill
NCT02936323 COMPLETED PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Tarveda Therapeutics
NCT04432467 COMPLETED Fertility Restoration Using Autologous Mesenchymal Stem Cells
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
NCT03430895 COMPLETED Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Memorial Sloan Kettering Cancer Center
NCT03720392 TERMINATED Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
Zachariah Michael DeFilipp
NCT02795520 TERMINATED Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
OncoTherapy Science, Inc.
NCT04761835 WITHDRAWN STEP-IT-UP - Peanut Allergy Study for Infants
Johns Hopkins University
NCT05007769 WITHDRAWN Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
Washington University School of Medicine
NCT04262869 WITHDRAWN Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
Emory University
NCT02657928 COMPLETED Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Mayo Clinic
NCT02853318 COMPLETED Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Roswell Park Cancer Institute
NCT03763630 COMPLETED MAPS & ITEC Cohorts: 6-8 Years Follow-up
University of Southampton
NCT04050215 COMPLETED 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT03742323 TERMINATED REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
PETHEMA Foundation
NCT04393220 COMPLETED Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
Fuda Cancer Hospital, Guangzhou
NCT03685695 COMPLETED Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Roswell Park Cancer Institute
NCT02631590 COMPLETED Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
H. Lee Moffitt Cancer Center and Research Institute
NCT04809649 WITHDRAWN SUBA-Itraconazole Therapy for Coccidioidomycosis Refractory or Intolerant to Fluconazole
George R Thompson
NCT03569098 COMPLETED Dysport in Hallux Abducto Valgus (HAV) Phase IIa
Ipsen
NCT03838731 COMPLETED Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge
Regeneron Pharmaceuticals
NCT03602898 WITHDRAWN Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT04611776 WITHDRAWN A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer
Hoffmann-La Roche
NCT02500550 COMPLETED Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
Kiadis Pharma
NCT03682965 COMPLETED Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
Christopher Thompson, MD
NCT03094611 TERMINATED Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT03076437 COMPLETED Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies
Shenzhen Institute for Innovation and Translational Medicine
NCT03275376 TERMINATED Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma
Taichung Veterans General Hospital
NCT03289455 COMPLETED CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
Autolus Limited
NCT04585932 WITHDRAWN Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study
M.D. Anderson Cancer Center
NCT03044626 COMPLETED Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC
AIO-Studien-gGmbH
NCT03739606 WITHDRAWN Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
NCT04127721 WITHDRAWN Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT02991898 TERMINATED Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT03106545 COMPLETED Liposome Bupivacaine for ANKLE Blocks
Catherine Vandepitte, M.D.
NCT02259582 COMPLETED A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer
OncoMed Pharmaceuticals, Inc.
NCT04106843 WITHDRAWN Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
M.D. Anderson Cancer Center
NCT03097770 COMPLETED Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
Chinese PLA General Hospital
NCT03299868 COMPLETED Comparison Between Initial Routine PICC and General IV Access in Terminally Ill Cancer Patients
Pusan National University Yangsan Hospital
NCT03887026 COMPLETED Efficacy and Safety of Norketotifen in Adults With Allergic Rhinitis
Emergo Therapeutics, Inc.
NCT02767934 TERMINATED Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
University of Washington
NCT03820908 COMPLETED Bisantrene for Relapsed /Refractory AML
Sheba Medical Center
NCT02193152 TERMINATED Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
NCT02885025 COMPLETED Effects of Broccoli Sprout Extract on Allergy Rhinitis
VA Office of Research and Development
NCT03359018 COMPLETED Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma
Peking University People's Hospital
NCT02237196 COMPLETED Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02535364 TERMINATED Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)
Juno Therapeutics, a Subsidiary of Celgene
NCT03181009 COMPLETED Multi OIT to Test Immune Markers After Minimum Maintenance Dose
Kari Christine Nadeau, MD PhD
NCT02912676 COMPLETED Thiopurine EnhAnced Maintenance Therapy
Kjeld Schmiegelow
NCT03838133 COMPLETED A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy
Taiwan Liposome Company
NCT02452463 TERMINATED Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy
Roswell Park Cancer Institute
NCT03123055 TERMINATED A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Rainier Therapeutics
NCT02315430 COMPLETED Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT03868241 COMPLETED Coated Devices to Decrease Infection in the Intensive Care Unit
Hospital do Coracao
NCT02401542 TERMINATED Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma
Rainier Therapeutics
NCT02692638 TERMINATED Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO
Yale University
NCT02819011 COMPLETED OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO
Bijan Najafi, PhD
NCT03368339 COMPLETED Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
Realm Therapeutics, Inc.
NCT02587650 TERMINATED Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
University of California, San Francisco
NCT02404220 TERMINATED Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Gilead Sciences
NCT03195010 TERMINATED Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
NCT03333278 COMPLETED The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial
Australian and New Zealand Intensive Care Research Centre
NCT02556801 COMPLETED Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
HAL Allergy
NCT02518113 COMPLETED A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
Eli Lilly and Company
NCT03343600 TERMINATED Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation
National Taiwan University Hospital
NCT02535806 TERMINATED Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
NCT02515123 COMPLETED Promotion of Oesophageal Motility to Prevent Regurgitation and Enhance Nutrition Intake in ICU Patients.
E-Motion Medical Ltd.
NCT02579876 COMPLETED Milk Patch for Eosinophilic Esophagitis
Children's Hospital of Philadelphia
NCT02993783 TERMINATED A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Millennium Pharmaceuticals, Inc.
NCT03472378 COMPLETED Can DFN-15 Terminate Migraine With Allodynia?
Hartford Hospital
NCT02518750 TERMINATED Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
NCT02871427 TERMINATED Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
Axovant Sciences Ltd.
NCT02948101 WITHDRAWN PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
NCT03394105 COMPLETED Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
Asan Medical Center
NCT03187691 WITHDRAWN Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Matinas BioPharma Nanotechnologies, Inc.
NCT02722083 TERMINATED Exploratory Study for Allergy Relief Onset
Bayer
NCT03438344 WITHDRAWN Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
NCT02538926 WITHDRAWN Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
University of Washington
NCT02311413 COMPLETED A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02632903 WITHDRAWN Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study
Children's Hospital of Eastern Ontario
NCT02339714 COMPLETED Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis
Zhao Hong
NCT02719405 TERMINATED Impact of Infant Formula on Resolution of Cow's Milk Allergy
Massachusetts General Hospital
NCT02419469 TERMINATED Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
NCT02535104 COMPLETED Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)
Tamir Biotechnology, Inc.
NCT03074136 COMPLETED Application of Photodynamic Therapy and Diode Laser for Endodontic Therapy of Young Permanent Teeth
Association of Paediatric and Preventive Dentists of Serbia
NCT02738060 COMPLETED The Effect of Baked Milk on Cow's Milk Allergy
Hossein Esmaielzadeh
NCT02269579 WITHDRAWN Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
Jazz Pharmaceuticals
NCT02590003 TERMINATED Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
Yale University
NCT03003663 COMPLETED Interrupted Time-Series Study for In-hospital Fall Reduction
MedicusTek, Inc
NCT02481323 COMPLETED Lacunar Intervention Trial 1 (LACI-1)
University of Edinburgh
NCT02640729 COMPLETED Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia
Axovant Sciences Ltd.
NCT02643862 COMPLETED Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients
Stanford University
NCT02626611 COMPLETED Multi Immunotherapy to Test Tolerance and Xolair
Kari Christine Nadeau
NCT02765997 WITHDRAWN StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Masonic Cancer Center, University of Minnesota
NCT02243449 COMPLETED Screening Elderly Patients for Weaning
Unity Health Toronto
NCT02576808 COMPLETED Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis
Thai Traditional Medical Knowledge Fund
NCT02544438 COMPLETED Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
BioSight Ltd.
NCT02801032 COMPLETED Effect of Tadalafil on Cerebral Large Arteries in Stroke
Christina Kruuse
NCT02887456 COMPLETED Endodontic Treatment of Primary Teeth Using Mineral Trioxide Aggregate Paste
University of Sao Paulo
NCT02382718 COMPLETED FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy
George Stavroulakis
NCT02763592 COMPLETED Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery
University Hospital, Clermont-Ferrand
NCT03094845 COMPLETED Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
ASIT Biotech S.A.
NCT02167360 WITHDRAWN Study of Efficacy and Safety of CTL019 in Adult ALL Patients
Abramson Cancer Center at Penn Medicine
NCT02481856 COMPLETED A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber
ALK-Abelló A/S
NCT03005392 COMPLETED Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
NCT02281279 WITHDRAWN Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Mayo Clinic
NCT02512653 COMPLETED Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)
Laboratorios Leti, S.L.
NCT02694770 WITHDRAWN A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
AbGenomics B.V Taiwan Branch
NCT02345278 COMPLETED SUBLIVAC FIX Mite Mixture Dose Tolerability Study
HAL Allergy
NCT02338050 TERMINATED Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research